Back to Search Start Over

Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER):a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial

Authors :
Ashina, Messoud
Lanteri-Minet, Michel
Pozo-Rosich, Patricia
Ettrup, Anders
Christoffersen, Cecilie Laurberg
Josiassen, Mette Krog
Phul, Ravinder
Sperling, Bjørn
Ashina, Messoud
Lanteri-Minet, Michel
Pozo-Rosich, Patricia
Ettrup, Anders
Christoffersen, Cecilie Laurberg
Josiassen, Mette Krog
Phul, Ravinder
Sperling, Bjørn
Source :
Ashina , M , Lanteri-Minet , M , Pozo-Rosich , P , Ettrup , A , Christoffersen , C L , Josiassen , M K , Phul , R & Sperling , B 2022 , ' Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER) : a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial ' , The Lancet Neurology , vol. 21 , no. 7 , pp. 597-607 .
Publication Year :
2022

Abstract

Background: The monoclonal antibody eptinezumab, which targets calcitonin gene-related peptide, has shown migraine preventive effects starting the day following infusion and acceptable safety and tolerability in phase 3 trials, but benefits in the subpopulations of patients with previous preventive treatment failures were not examined. We aimed to investigate the safety and efficacy of eptinezumab for migraine prevention in adults with migraine and two-to-four previous preventive treatment failures. Methods: DELIVER was a multicentre, multi-arm, phase 3b trial comprising a 24-week double-blind, placebo-controlled period and a 48-week dose-blinded extension. We recruited adults with episodic or chronic migraine with at least 4 monthly migraine days (as per International Headache Society guidelines) and documented evidence of two-to-four previous preventive treatment failures within the past 10 years, from 96 study locations across Europe (n=93) and the USA (n=3). Patients were randomly assigned (1:1:1) via a centralised randomisation system, stratified by baseline monthly headache days and country, to eptinezumab 100 mg, eptinezumab 300 mg, or placebo. The primary efficacy endpoint was the change from baseline in mean monthly migraine days (captured using a daily electronic diary) in weeks 1–12, assessed in the full analysis set. All participants and study personnel were masked to study drug assignments. The dose-blinded extension period is ongoing. The trial is registered with ClinicalTrials.gov, NCT04418765, and EudraCT, 2019-004497-25. Findings: Between June 1, 2020, and Oct 7, 2021, 891 individuals were randomly assigned and received at least one dose of study drug (safety population; eptinezumab 100 mg n=299 [34%], eptinezumab 300 mg n=294 [33%], placebo n=298 [33%]). 865 patients completed the placebo-controlled period. The change from baseline to weeks 1–12 in mean monthly migraine days was –4·8 (SE 0·37) with eptinezumab 100 mg, –5·3 (0·37) with eptinezuma

Details

Database :
OAIster
Journal :
Ashina , M , Lanteri-Minet , M , Pozo-Rosich , P , Ettrup , A , Christoffersen , C L , Josiassen , M K , Phul , R & Sperling , B 2022 , ' Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER) : a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial ' , The Lancet Neurology , vol. 21 , no. 7 , pp. 597-607 .
Notes :
English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1382519991
Document Type :
Electronic Resource